Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial
- Submitting institution
-
Cardiff University / Prifysgol Caerdydd
- Unit of assessment
- 1 - Clinical Medicine
- Output identifier
- 95827112
- Type
- D - Journal article
- DOI
-
10.1016/S1470-2045(15)00193-X
- Title of journal
- Lancet Oncology
- Article number
- -
- First page
- 1295
- Volume
- 16
- Issue
- 13
- ISSN
- 1470-2045
- Open access status
- Out of scope for open access requirements
- Month of publication
- September
- Year of publication
- 2015
- URL
-
http://dx.doi.org/10.1016/S1470-2045%2815%2900193-X
- Supplementary information
-
https://www.thelancet.com/cms/10.1016/S1470-2045%2815%2900193-X/attachment/cf41bccc-c18e-4f00-8481-7e00f1a12897/mmc1.pdf
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
15
- Research group(s)
-
-
- Citation count
- 220
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
-
- Author contribution statement
- a: The author made a substantial contribution to: the organisation of the conduct of the study; carrying out the study (including acquisition of study data); analysis and interpretation of study data.
b: The author helped draft the output.
- Non-English
- No
- English abstract
- -
